Anxiety DisordersDepressive DisordersPTSDVeteransTraumatic Brain Injury (TBI)Neurological InjuryNeuroimaging & Brain MeasuresPsilocybin

Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreat

In a preliminary uncontrolled study of 21 veterans with traumatic brain injury, participation in two psilocybin retreat ceremonies was associated with large reductions in PTSD, depression and anxiety symptoms and with EEG changes (reduced frontal/temporal delta–theta power and increased alpha–beta coherence) consistent with improved emotional regulation and neural communication. These findings suggest psilocybin retreats may improve psychological wellbeing and brain connectivity in veterans with TBI and warrant larger, controlled trials.

Authors

  • Robin Carhart-Harris
  • Leor Roseman
  • David Erritzoe

Published

Frontiers in Psychiatry
individual Study

Abstract

Introduction

Psilocybin, a serotonergic psychedelic, has shown therapeutic potential in treating mental health disorders by, amongst the many effects, promoting neuroplasticity and reorganising functional connectivity across cortical and subcortical networks involved in emotion and cognition. Veterans with traumatic brain injuries (TBI) often experience chronic neurological and psychological symptoms such as post-traumatic stress disorder (PTSD) and depression. This study investigates the effects of psilocybin administered in retreat settings on veterans with a history of TBI, focusing on mental health outcomes and changes in brain connectivity as measured by EEG.

Methods

A total of 21 participants were recruited through the Heroic Hearts Project, which facilitated access to two six-day psilocybin retreats in Jamaica. Before the retreat, participants underwent three individual and three group coaching sessions to prepare for the experience. During the retreat, two psilocybin ceremonies were held, spaced 48 hours apart. Participants received an initial dose of 1.5g to 3.5g of dried psilocybin mushrooms, with the option to increase the second dose up to 5g. Psilocybin was administered in a tea format, under the supervision of experienced facilitators. Psychological outcomes were assessed using validated questionnaires (PCL-5, PHQ-9, STAI) at baseline (four weeks pre-retreat) and four weeks post-retreat. Electroencephalography (EEG) was used to measure brainwave activity pre- and post-treatment. Paired t-tests were used to analyze changes in psychological scores, while EEG frequency band analysis assessed changes in brain function and connectivity.

Results

Improvements were observed across several mental health measures: PTSD (PCL-5 scores decreased by 50%, p=0.010), depression (PHQ-9 scores decreased by 65%, p<0.001), and anxiety (STAI) scores decreased by 28%, p<0.001). EEG data showed decreased delta and theta power in frontal and temporal regions, indicating potential improvements in cognitive control and emotional processing. Enhanced coherence in alpha and beta bands suggested improved neural communication.

Discussion

The study suggests that psilocybin retreats might provide improvements in psychological well-being and brain connectivity in veterans with TBI. Reduced delta power and normalised theta activity suggest better emotional regulation, while improved coherence in alpha and beta bands may reflect increased cognitive engagement. Further, these preliminary outcomes provide a potential rationale for the design and implementation of larger-scale, controlled studies to validate and expand upon these initial findings.

Available with Blossom Pro

Research Summary of 'Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreat'

Introduction

Psilocybin is a serotonergic psychedelic that acts mainly at 5-HT2A receptors and has been proposed to promote neuroplasticity and to reorganise functional connectivity in networks supporting emotion and cognition. Veterans are at elevated risk of traumatic brain injury (TBI) and commonly experience chronic neurological and psychiatric sequelae such as depression, anxiety and post-traumatic stress disorder (PTSD). Electroencephalography (EEG) studies of TBI have repeatedly documented persistent abnormalities in spectral power and coherence, most notably elevated slow-wave activity in delta and theta bands and attenuated alpha and beta rhythms, which are thought to reflect disrupted thalamocortical and cortical network function. Blest-Hopley and colleagues set out to evaluate whether participation in residential psilocybin retreats was associated with improvements in mental health and concomitant changes in resting-state EEG among veterans reporting prior TBI. The authors hypothesised that retreat attendance would reduce delta power and normalise theta activity, while increasing alpha and beta power and coherence, with effects localising primarily to frontal and temporal regions. Psychological outcomes were to be measured with validated questionnaires and neurofunctional changes assessed using pre- and post-retreat EEG recordings collected at the retreat site.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Pro members can view the original manuscript directly in the browser.

Study Details

References (23)

Papers cited by this study that are also in Blossom

Emotions and brain function are altered up to one month after a single high dose of psilocybin

Barrett, F. S., Doss, M. K., Sepeda, N. D. et al. · Scientific Reports (2020)

Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat

Smigielski, L., Kometer, M., Scheidegger, M. et al. · Scientific Reports (2019)

126 cited
Trial of Psilocybin versus Escitalopram for Depression

Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)

927 cited
Psychedelics for Brain Injury: A Mini-Review

Khan, S. I., Carter, G. T., Aggarwal, S. K. et al. · Frontiers in Neuroscience (2021)

Reviewing the potential of psychedelics for the treatment of PTSD

Krediet, E., Bostoen, T., Breeksema, J. J. et al. · International Journal of Neuropsychopharmacology (2020)

Psychedelics

Nichols, D. E. · Pharmacological Reviews (2016)

Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens

Rickli, A., Moning, O. D., Hoener, M. C. et al. · European Neuropsychopharmacology (2016)

Show all 23 references
Human hallucinogen research: guidelines for safety

Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)

Therapeutic use of psilocybin: Practical considerations for dosing and administration

MacCallum, C. A., Pistawka, C. A., Deol, J. K. et al. · Frontiers in Psychiatry (2022)

Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees

Kiraga, M. K., Kuypers, K. P. C., Uthaug, M. V. et al. · Frontiers in Psychiatry (2022)

20 cited
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up

Davis, A. K., Streeter Barrett, F., Cosimano, M. P. et al. · Journal of Psychopharmacology (2022)

306 cited
The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis

Goldberg, S. B., Pace, B. T., Nicholas, C. R. et al. · Psychiatry Research (2020)

Ayahuasca in the treatment of posttraumatic stress disorder: Mixed-methods case series evaluation in military combat veterans

Weiss, B., Dinh-Williams, L. A. L., Beller, N. et al. · Psychological Trauma (2024)

Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential

Allen, J., Dames, S., Foldi, C. J. et al. · Molecular Psychiatry (2024)

Psychedelics promote structural and functional neural plasticity

Ly, C., Greb, A. C., Cameron, L. P. et al. · Cell Reports (2018)

Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior

Gonza ´lez-Maeso, J., Weisstaub, N. V., Zhou, M. et al. · Neuron (2007)

818 cited
Psilocybin Combines Rapid Synaptogenic And Anti-Inflammatory Effects In Vitro

Smedfors, G., Glotfelty, E., Papatziamos, C. et al. · Research Square (2022)

The DMT and Psilocin Treatment Changes CD11b+ Activated Microglia Immunological Phenotype

Kozłowska, U., Klimczak, A., Wiatr, K. et al. · Biorxiv (2021)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.

Improved mental health outcomes and normalised... — Research Summary & Context | Blossom